4102-84-5

Usage

Uses

Used in Personal Care Industry:
6-chloro-4-nitro-o-cresol is used as a preservative in personal care products for its antimicrobial properties, ensuring the safety and longevity of products such as soaps, shampoos, lotions, and skincare products by preventing the growth of harmful microorganisms.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 6-chloro-4-nitro-o-cresol is utilized as a preservative in various formulations to maintain sterility and prevent contamination by bacteria and fungi, thereby ensuring the efficacy and safety of the medications.

InChI:InChI=1/C7H6ClNO3/c1-4-2-5(9(11)12)3-6(8)7(4)10/h2-3,10H,1H3

Upstream product

• 861366-88-3 2-chloro-6-methyl-[1,4]benzoquinone-4-oxime 
• 6265-03-8 2-amino-6-methyl-4-nitro-phenol 
• 99-53-6 2-methyl-4-nitrophenol 
• 95-48-7 ortho-cresol 
• 1123-64-4 2-chloro-6-methyl-[1,4]benzoquinone 
• 859495-20-8 5-chloro-6-hydroxy-toluene-3-sulfonic acid 

Downstream Products

• 55411-44-4 3-chloro-4-hydroxy-5-methyl aniline 

Relevant academic research and scientific papers

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity against VEGFR2, p38α, and B-Raf

A series of diarylurea inhibitors of the cardiac-specific kinase TNNI3K were developed to elucidate the biological function of TNNI3K and evaluate TNNI3K as a therapeutic target for the treatment of cardiovascular diseases. Utilizing a structure-based design, enhancements in kinase selectivity were engineered into the series, capitalizing on the established X-ray crystal structures of TNNI3K, VEGFR2, p38α, and B-Raf. Our efforts culminated in the discovery of an in vivo tool compound 47 (GSK329), which exhibited desirable TNNI3K potency and rat pharmacokinetic properties as well as promising kinase selectivity against VEGFR2 (40-fold), p38α (80-fold), and B-Raf (>200-fold). Compound 47 demonstrated positive cardioprotective outcomes in a mouse model of ischemia/reperfusion cardiac injury, indicating that optimized exemplars from this series, such as 47, are favorable leads for discovering novel medicines for cardiac diseases.

THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

COMPOUNDS AND METHODS

Disclosed are compounds having the formula: wherein R1 and R2 are as defined herein, and methods of making and using the same.